Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 488 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
488 trials meet filter criteria.
Sort by:
TrialFetch AI summary: For patients with unresectable locally advanced or metastatic KRAS-mutated or KRAS-amplified solid tumors who have received, are ineligible for, or decline standard care, this study evaluates BMS-986523 alone or with pembrolizumab, cetuximab, or gemcitabine plus nab-paclitaxel. BMS-986523 is an investigational protein-degradation therapy with an undisclosed target; the pembrolizumab arm additionally requires PD-L1 expression ≥50%.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors harboring any KRAS mutation or wild-type KRAS amplification receive intravenous PT0511, an investigational pan-KRAS protein degrader. A colorectal cancer expansion cohort receives PT0511 plus cetuximab, an anti-EGFR antibody.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic EGFR-mutated NSCLC that has progressed after first- or second-line osimertinib receive escalating doses of NXP900 plus osimertinib. NXP900 is an investigational oral inhibitor of SRC-family kinases, particularly YES1 and SRC.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: Adults with advanced or unresectable solid tumors harboring ERBB2 alterations, NRG1 fusions, or HER2 overexpression receive oral CGT4255, an investigational HER2 inhibitor designed to target mutant and wild-type HER2 while sparing EGFR. Expansion cohorts focus on ERBB2-mutated NSCLC and ERBB2-mutated or HER2-overexpressing breast cancer, including patients with brain metastases.
ClinicalTrials.gov ID: NCT07361562
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic urothelial carcinoma, NSCLC, gastric or gastroesophageal junction cancer, or HER2-negative breast cancer may be eligible, depending on cohort-specific prior therapy requirements. ASP2998, a TROP2-targeted antibody–drug conjugate carrying topoisomerase I inhibitor and STING agonist payloads, is given alone or with pembrolizumab, carboplatin, or enfortumab vedotin.
ClinicalTrials.gov ID: NCT07287995
TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: For patients with relapsed or refractory SCLC after at least one platinum-based chemotherapy regimen, this study evaluates investigational BMS-986525 alone or with nivolumab (anti-PD-1). BMS-986525’s molecular target and mechanism have not been disclosed.
ClinicalTrials.gov ID: NCT07325136
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808